GLD’s sole mission is to service the dire unmet needs of the global Lyme community with a new diagnostic solution specific to Lyme Disease that is grounded in science. The company’s test will help decrease the number of patients being misdiagnosed. The new test kits are available now.
[Research Triangle Park, NC June 29, 2017] A recent piece on NBC News With Lester Holt presented some startling facts regarding Lyme Disease. Cases of Lyme Disease are up 500% in Michigan alone. Lyme Disease is spreading across the US and we can expect to see the number of patients infected increase in 2017.
As published in the journal Science, Lyme disease carrying ticks are now present in half the counties in the United States. In many instances physicians in these counties are not aware the Lyme endemic region has moved to them. There are an abundance of articles, including USA Today, Washington Times, Fox News.com and NPR.com, predicting 2017 will potentially be the worst year for Lyme disease.
Misdiagnosis is also a core issue, as Lyme Disease can masquerade as many things – juvenile arthritis, fibromyalgia, chronic fatigue syndrome, multiple sclerosis and a host of other maladies. The Lyme community today faces 2 challenges – clinicians rightfully don’t trust current tests and second the need to generate awareness in a clinical practices that are the first line of defense in this battle to get tests prescribed.
All of this has scientists rushing to develop new blood testing methods, as noted recently in a piece on Today.com, written by Linda Carroll. But what is needed is a test grounded in real science.
Global Lyme Diagnostics hopes to address these challenges with a breakthrough test specifically for Lyme Disease. It is a focused solution that works and test kits are available now.
The new test was invented by Dr. Richard T. Marconi. Dr. Marconi, a Professor in the School of Medicine at Virginia Commonwealth University Medical Center, has spent decades researching Lyme disease. The primary focus of current research in the Marconi lab is to advance human health through the development of next generation vaccines, diagnostic assays and novel therapeutic approaches for infections caused by pathogenic spirochetes and tick-borne pathogens.
“We are excited to launch this new Lyme screening test that provides clinicians with a better tool to help in their clinical diagnosis and help manage their patients,” stated Mickey Ramchandani, CEO of Global Lyme Diagnostics. “Unlike many tests recently launched, our vanguard new Lyme test is grounded in science, developed by researchers who have dedicated their careers to Lyme disease and a company led by scientists and clinicians who put science and patients first.”
Dr. Marconi’s research has led to this novel breakthrough called chimeritopes which increase sensitivity by eliminating proteins that are not relevant to a Lyme infection (non-OsPC targets) and can further reduce false negatives by targeting Lyme causing bacteria variants across the North American spectrum. ALL DONE IN ONE TEST MAKING IT AN AFFORDABLE SOLUTION FOR A BETTER, MORE DIVERSE SCREEN.
After licensing this technology platform and related intellectual property developed in Dr. Richard Marconi’s lab at Virginia Commonwealth University, GLD focused on creating a highly accurate and reproducible solution. After years of research GLD has just launched the test and kits which can be requested at https://glymedx.com/clinicians/.
GLD’s test keeps the prescribing by clinicians simple and doesn’t require any new training or equipment for the physician’s office. The test is a simple blood draw, something clinicians are very familiar with, eliminating the need to invest in training or equipment.
Dr. Marconi is well recognized for his diverse research efforts and has lectured worldwide. He has served as the President of the Virginia Branch of the American Society for Microbiology, participated in over 120 national and international review panels and published more than 100 peer reviewed research articles and reviews. He has authored two definitive book chapters on Lyme Disease vaccines and is on the scientific boards of multiple organizations, including GLD and Global Lyme Alliance.
More information about GLD, including the science behind the new test and the Global Lyme Diagnostics team is available at the website at http://www.glymedx.com.
About Global Lyme Diagnostics:
GLD was formed with the sole purpose of providing a solution to the Lyme community including, physicians, clinicians, patients, advocates and families. Its initial focus is to develop and launch a test that is grounded in science and provides an answer to the challenges related to tests on the market. In addition to launching of their new test, GLD is working with the Lyme community and physicians to develop screening opportunities for worried individuals in Lyme endemic areas to help reduce long term complications. GLD is also researching methods to detect co-infections, as well as, assays that could differentiate early stage versus late stage infections for clinicians to better manage their patients.
Elizabeth Leed, Director of Marketing
Global Lyme Diagnostics